WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes

Diabetic Medicine

Volumn 21, Issue 4, 2004, Pages 383-387

  Marchesini, G ^a   Forlani, G ^a   Cerrelli, F ^a   Manini, R ^a   Natale, S ^a   Baraldi, L ^a   Ermini, G ^b   Savorani, G ^b   Zocchi, D ^b   Melchionda, N ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ASL   (Italy)

Author keywords

Cholesterol; Hypertension; Microalbuminuria; Obesity; Waist circumference

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTHROPOMETRY; ARTERIAL PRESSURE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DISABILITY; FEMALE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX RATIO; WORLD HEALTH ORGANIZATION;

AGED; ALBUMINURIA; BODY CONSTITUTION; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION;

EID: 11144358451     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01115.x     Document Type: Article

References (29)

1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
2. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520.
3. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999: 31-33.
4. WHO Guidelines Subcommittee. 1999 World Health Organization- International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
5. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
6. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001; 44: 1148-1154.
7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
8. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the strong heart study. Diabetes Care 2003; 26: 861-867.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
10. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-1289.
11. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
12. Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. Int J Obes Relat Metab Disord 1999; 23: 116-125.
13. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-161.
14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
15. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001; 24: 1758-1763.
16. Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS, Thomas GN et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 2001; 25: 1782-1788.
17. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350.
18. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683-1687.
19. Balkau B, Charles MA, for the European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16: 442-443.
20. Liese AD, Hense HW, Doring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001; 15: 799-804.
21. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165.
22. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307-313.
23. Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152: 908-911.
24. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479-486.
25. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002; 25: 718-723.
26. Cuspidi C, Lonati L, Sampieri L, Macca G, Valagussa L, Zaro T et al. Blood pressure control in a hypertension hospital clinic. J Hypertens 1999; 17: 835-841.
27. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
28. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
29. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001; 24: 1936-40.